Welcome to our dedicated page for SARTORIUS STEDIM BIOTECH news (Ticker: SDMHF), a resource for investors and traders seeking the latest updates and insights on SARTORIUS STEDIM BIOTECH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SARTORIUS STEDIM BIOTECH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SARTORIUS STEDIM BIOTECH's position in the market.
Sartorius Stedim Biotech has partnered with McMaster University to enhance the manufacturing processes of antibody and virus-based treatments, including COVID-19 therapies. Utilizing a multi-column chromatography system, this collaboration aims to develop more effective and cost-efficient virus purification methods. The four-year project supports the United Nations' Sustainable Development Goals, promoting wider access to biotherapeutics. Additionally, Sartorius will provide training for students at its facilities in North America and Europe, fostering the next generation of leaders in biomanufacturing.
Sartorius Stedim Biotech has acquired Xell AG, a cell culture specialist based in Germany, for approximately 50 million euros, with additional earn-out components tied to revenue targets from 2022 to 2025. Xell AG, which employs about 35 people, is expected to generate around 5 million euros in sales with strong growth and a substantial EBITDA margin in 2021. This acquisition aims to enhance Sartorius's media offerings for viral vector manufacturing and accelerate the expansion of its production network in this fast-growing market.
Sartorius Stedim Biotech reported strong growth in H1 2021, with sales revenue increasing by 61.1% to 1,352 million euros. Order intake rose by 87.4%, driven by high demand, especially from coronavirus vaccine manufacturers. The company raised its full-year sales growth forecast to around 48% and underlying EBITDA margin to 36%. The workforce increased by 15.6% to 8,746 employees. Despite uncertainties related to the pandemic, management remains optimistic about future growth, supported by ongoing production expansions and acquisitions.
Sartorius Stedim Biotech reported a projected 61% revenue growth for the first half of 2021, alongside an underlying EBITDA margin between 36.0% and 36.5%. This performance reflects robust order intake and stable supply chains. The company has revised its full-year forecast upwards, estimating 48% sales growth (previously 38%) and maintaining an EBITDA margin of about 36%. Risks associated with the pandemic persist, affecting guidance reliability. Detailed half-year figures will be released on July 21, 2021.
Sartorius Stedim Biotech has acquired a 51% stake in CellGenix GmbH for approximately 100 million euros. Based in Freiburg, Germany, CellGenix specializes in cell culture components for cell and gene therapies and reported over 20 million euros in sales in 2020. This strategic acquisition is aimed at expanding Sartorius's product portfolio and enhancing its global sales capabilities. Plans are in place for Sartorius to acquire the remaining shares by 2026, with an emphasis on developing the Freiburg site as a center of excellence for critical raw materials in biopharma.
Sartorius Stedim Biotech reported a strong start to fiscal 2021 with sales revenue rising 61.1% to 655 million euros, driven by demand from vaccine manufacturers and acquisitions. Order intake nearly doubled to 1,004 million euros, reflecting changing customer ordering patterns. Underlying EBITDA increased 82.8% to 232 million euros with a margin of 35.4%. The company confirmed its full-year forecast projecting 38% sales growth and a 33% EBITDA margin.
Sartorius Stedim Biotech S.A. announced that during its virtual Annual General Shareholders' Meeting, shareholders approved a dividend payment of 0.68 euros per share for fiscal 2020, translating to a total distribution of 62.7 million euros. This represents a doubling of the previous year's dividend of 0.34 euros per share. The meeting also saw a significant majority granting discharge to all directors. The company continues to see strong growth, employing over 7,500 individuals and reporting 1,910 million euros in sales revenue for 2020.
Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021 due to strong order intake and increased demand, particularly related to coronavirus vaccine production. Consolidated sales growth is now projected at 38%, up from the previous 20-26%. The underlying EBITDA margin is expected to be about 33%. The CAPEX ratio is now projected at 14%, while net debt to underlying EBITDA is expected to be around 0.6 by year-end. The guidance remains uncertain due to potential supply chain disruptions but is not expected to affect mid-term targets updated in January 2021.
Sartorius Stedim Biotech reported a 34.6% increase in sales revenue, reaching 1,910 million euros in 2020. The underlying EBITDA margin improved to 31.7%, with net profit rising 45.9% to 384 million euros. Management forecasts a 20%-26% sales growth for 2021 and has raised its 2025 sales target to 4 billion euros. The group anticipates a 15% CAPEX ratio for 2021 to enhance production capacities, responding to strong order intake growth of 56.7% to 2,381 million euros.
The Board of Directors of Sartorius Stedim Biotech has proposed a dividend of 0.68 euros per share for fiscal 2020, to be voted on at the Annual General Shareholders' Meeting on March 24, 2021. This proposed dividend represents a total distribution of €62.7 million, a significant increase from last year's dividend of 0.34 euros. Sartorius is a key player in the biopharmaceutical industry, with projected sales revenue of approximately 1,910 million euros for 2020.
FAQ
What is the market cap of SARTORIUS STEDIM BIOTECH (SDMHF)?
